Quince Therapeutics, Inc. (QNCX) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 1.63
30Y Low0.2·High9.3
ROE
↓
N/A
—
5yr avg: -60.4%
30Y Low-99%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
QNCX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Quince Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $168M | $81M | $39M | $21M | $375M | $811M | $1.1B | — | — |
| Enterprise Value | $20M | $180M | $89M | $32M | $-22788710 | $306M | $744M | $1.0B | — | — |
| P/E Ratio → | -0.08 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 2.68 | 0.46 | 0.21 | 3.16 | 4.71 | 9.25 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
QNCX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
QNCX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -98.6% | -33.8% | -47.1% | -61.9% | -53.4% | -39.6% | -48.8% | — |
| ROA | -80.7% | -80.7% | -38.6% | -22.1% | -43.6% | -55.7% | -49.0% | -37.5% | -31.0% | -158.5% |
| ROIC | -485.6% | -485.6% | -73.5% | -38.6% | -73.3% | -86.9% | -69.6% | -53.0% | -69.7% | — |
| ROCE | -64.0% | -64.0% | -41.2% | -25.5% | -47.3% | -62.0% | -54.8% | -41.9% | -31.3% | -174.1% |
QNCX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $13M ($18M total debt minus $6M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.49 | 0.16 | 0.00 | 0.01 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 0.29 | -0.08 | -0.44 | -0.58 | -0.39 | -0.44 | -0.35 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -90.12 | — | — | — | -12.04 | -6.31 |
QNCX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.53x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 8.09x to 0.53x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.53 | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 | 8.11 | 11.93 | 49.82 | 4.28 |
| Quick Ratio | 0.53 | 0.53 | 6.05 | 8.09 | 30.55 | 7.85 | 8.11 | 11.93 | 49.82 | 4.28 |
| Cash Ratio | 0.41 | 0.41 | 5.60 | 7.84 | 29.38 | 7.51 | 7.87 | 11.23 | 49.22 | 4.17 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
QNCX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Quince Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $5M | $4M | $4M | $3M | $3M | $3M | $2M | $2M | $2M |
Peer Comparison
Compare QNCX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 QNCXYou | $7M | -0.1 | — | — | — | — | — | -485.6% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.8 | 26.7 | 36.5 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $6B | 9.5 | 6.3 | 8.7 | 95.9% | 49.5% | — | — | 0.5 |
 KRYS | $9B | 44.7 | 50.8 | 47.7 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCKT | $396M | -1.8 | — | — | — | — | -60.3% | -62.4% | — |
 SRPT | $2B | -2.8 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 BMRN | $10B | 30.0 | 15.9 | 14.3 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 ALGS | $40M | -2.6 | — | — | 57.5% | -4024.9% | -196.9% | -163.0% | — |
 PRAX | $10B | -24.5 | — | — | — | — | -45.8% | -65.0% | — |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See QNCX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QNCX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QNCX vs RARE
Side-by-side business, growth, and profitability comparison vs Ultragenyx Pharmaceutical Inc..
Start ComparisonQNCX — Frequently Asked Questions
Quick answers to the most common questions about buying QNCX stock.
What is Quince Therapeutics, Inc.'s P/E ratio?
Quince Therapeutics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Is QNCX stock overvalued?
Based on historical data, Quince Therapeutics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.